Company intelligence / Profile preview
Repertoire Immune Medicines
- Ownership
- Private
- Employees
- ~120
- Development stage
- Phase 1
Overview
Repertoire Immune Medicines has advanced a novel multi-clonal T cell therapy into clinical trials for metastatic solid tumors. Its lead program, RPTR‑168, delivers IL‑12 to enhance anti-tumor activity. The company’s DECODE™ platform has demonstrated effectiveness in identifying highly prevalent immunogenic epitopes relevant to both cancer and autoimmunity. Recent partnerships with Genentech and Bristol Myers Squibb validate the breadth of its target discovery capabilities but detailed clinical efficacy results have not yet been published as of May 2025.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- T cell therapies (multi-clonal cytokine-enhanced T cells)TCR bispecific moleculesmRNA cancer vaccinesmRNA tolerizing vaccines
- Industry
- Biotech
Drug pipeline
17 assets16 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Repertoire Immune Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Repertoire Immune Medicines.